The estimated Net Worth of Paul A. Stone is at least $1.51 Milion dollars as of 29 August 2023. Mr. Stone owns over 5,000 units of IDEAYA Biosciences stock worth over $336,769 and over the last 5 years he sold IDYA stock worth over $407,445. In addition, he makes $762,247 as Chief Financial Officer at IDEAYA Biosciences.
Paul has made over 10 trades of the IDEAYA Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of IDYA stock worth $144,350 on 29 August 2023.
The largest trade he's ever made was buying 250,000 units of IDEAYA Biosciences stock on 28 May 2019 worth over $2,500,000. On average, Paul trades about 18,194 units every 97 days since 2019. As of 29 August 2023 he still owns at least 9,303 units of IDEAYA Biosciences stock.
You can see the complete history of Mr. Stone stock trades at the bottom of the page.
Paul A. Stone J.D. serves as Chief Financial Officer of the Company. As Chief Financial Officer, he will lead the finance, investor relations, and public relations functions, and will continue as the Principal Financial and Accounting Officer. Paul will also continue to oversee the legal function as General Counsel. Prior to joining IDEAYA, Paul was with 5AM Ventures in various capacities including as Partner, General Counsel, and Chief Operating Officer, and held early management and operating roles in companies launched at 5AM Ventures, including IDEAYA Biosciences (NASDAQ: IDYA), Homology Medicines, Cidara Therapeutics, and Entrada Therapeutics. Paul earlier served in management roles at Ethos Pharmaceuticals, Ilypsa (acquired by Amgen), and Symyx Technologies.
As the Chief Financial Officer of IDEAYA Biosciences, the total compensation of Paul Stone at IDEAYA Biosciences is $762,247. There are 1 executives at IDEAYA Biosciences getting paid more, with Yujiro Hata having the highest compensation of $2,020,990.
Paul Stone is 56, he's been the Chief Financial Officer of IDEAYA Biosciences since 2019. There are 6 older and 10 younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences, Inc. is Wendy Yarno, 65, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at IDEAYA Biosciences have traded over $13,169,580 worth of IDEAYA Biosciences stock and bought 2,220,527 units worth $22,722,236 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Timothy M Shannon a X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of $2,196,906. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth $415,571.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences executives and other stock owners filed with the SEC include: